Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02240784 · ClinicalTrials.gov registry record
EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
A clinical trial, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- 136
- Enrollment target
NCT02240784: Completed study, sponsored by Alnylam Pharmaceuticals.
NCT02240784 is a clinical trial that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 136 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02240784 has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the natural history and clinical management of Acute Hepatic Porphyria (AHP) patients with recurring attacks.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2014-08 |
| Est. Completion | 2021-04-26 |
What the finished NCT02240784 record still lists
NCT02240784 is an observational study that tracks outcomes without assigning an intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02240784 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02240784 about?
NCT02240784 is a clinical study titled "EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)". The purpose of this study is to characterize the natural history and clinical management of Acute Hepatic Porphyria (AHP) patients with recurring attacks.
What is the current status of trial NCT02240784?
This trial is currently completed. The enrollment target is 136 participants. The study started on 2014-08. Estimated completion is 2021-04-26.
Who is sponsoring clinical trial NCT02240784?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia